Sera Prognostics (SERA)
(Real Time Quote from BATS)
$9.11 USD
-0.35 (-3.70%)
Updated Mar 28, 2024 01:20 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
SERA 9.11 -0.35(-3.70%)
Will SERA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for SERA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SERA
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
SERA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy
Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
Other News for SERA
iBio, Mesoblast, Kodiak Sciences among healthcare movers
Chief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)
Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA)
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health